Olumiant® (Baricitinib)

Para consultar la información para prescribir completa de Olumiant® (Baricitinib) de clic en el siguiente enlace: Información para prescribir

La información es proporcionada en respuesta a su solicitud, y puede contener datos relacionados a dosis, usos, formulaciones y poblaciones diferentes a la Información para Prescribir del producto. Consulte la Información para Prescribir en la liga que aparece arriba.

Baricitinib: Dosing for Moderate to Severe Rheumatoid Arthritis

La dosis recomendada para baricitinib (BARI) en pacientes adultos con artritis reumatoide moderada a severamente activa es de 4 mg una vez al día.

Dose Modifications

For some patients, a dose of 2 mg once daily may be acceptable.1

  • The recommended dose of BARI in patients with eGFR between 30 and 60 mL/min/1.73 m2 is 2 mg once daily. 1

  • The recommended dose of BARI in patients taking OAT3 inhibitors with a strong inhibition potential, such as probenecid, is 2 mg once daily.1

  • Clinical experience in patients ≥ 75 years is very limited and in these patients a starting dose of 2 mg is appropriate.1

Use of BARI is not recommended in patients with

  • estimated glomerular filtration rate of < 30 mL/min/1.73 m2.

  • severe hepatic impairment

  • absolute lymphocyte count <500 cells/mm3

  • absolute neutrophil count <1000 cells/mm3, or

  • hemoglobin level <8 g/dL.2

Use of BARI is not recommended in pediatric patients.1 

Dose Administration

Route of Administration

The appropriate BARI dose is given by mouth once daily.2

Food Effects

Administration with meals is not associated with a clinically relevant effect on exposure.2

An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean area under the curve and maximum serum concentration of BARI by approximately 11% and 18%, respectively, and delayed the time to reach maximum serum concentration by 0.5 hours.2

In clinical studies, BARI was administered without regard to meals.2


Baricitinib can be taken at any time of day or night. It is best to take BARI at the same time every day.1

Use With Other RA Therapies

Baricitinib may be used as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs DMARDs.2

Limitation of Use

Use of BARI is not recommended in combination with

  • other Janus kinase inhibitors

  • biologic DMARDs, or

  • potent immunosuppressents, such as azathioprine and cyclosporine.2


1. Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.


BARI = baricitinib

DMARD = disease-modifying antirheumatic drug

eGFR = estimated glomerular filtration rate

JAK = Janus kinase

OAT = organic anion transporter

Fecha de la última revisión: 2019 M04 30

Contáctenos para saber más de la información Médica de Lilly

Contacto vía correo electrónico

Correo electrónico: infomed@lilly.com

Envíe su consulta

Escriba su consulta